|Mr. Charles R. Kummeth||CEO, Pres & Director||2.56M||N/A||1960|
|Mr. James T. Hippel||Sr. VP of Fin. & CFO||968.88k||N/A||1971|
|Ms. Brenda S. Furlow||Gen. Counsel, Sec. & Chief Compliance Officer||643.23k||N/A||1958|
|Mr. N. David Eansor||Pres of Protein Sciences Segment||866.28k||N/A||1961|
|Mr. Gerry Andros||VP of Sales and Marketing||N/A||N/A||N/A|
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Corporation’s ISS Governance QualityScore as of November 1, 2018 is 1. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 1; Compensation: 3.